Screening for Obstructive Respiratory Disorders in the General Population During the "Mai Poumon 2026" Prevention Campaign: Prevalence and Impact on the Care Pathway (Mai Poumons 26)

Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.

Study Overview

• Status: Not yet recruiting
• Conditions: Chronic Obstructive Lung Disease; Airflow Obstruction
• Intervention / Treatment: Diagnostic test: Spirometry

Detailed Description

Chronic Obstructive Pulmonary Disease (COPD), a chronic bronchial disease characterized by irreversible airway obstruction, represents a major public health issue. It is currently the fifth leading cause of death worldwide and, according to the World Health Organization (WHO), is expected to become the third leading cause by 2030. Diagnosis is currently based on spirometry, which reveals an obstructive ventilatory disorder (OVD) defined by a forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of less than 0.7. However, limited access to this examination can make the diagnosis of COPD difficult. Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. A French study involving 424 patients hospitalized for a COPD exacerbation found that 21.9% had not been diagnosed previously, meaning they entered the disease during a severe exacerbation. The main challenge, therefore, lies in the early identification of COPD patients, particularly through the use of validated self-questionnaires (e.g., Haute Autorité de Santé). We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population. The secondary objectives are: to compare the clinical characteristics of patients with and without AO / with and without PRISm (depending on sample size). To identify risk factors for AO and/or PRISm (depending on sample size) (female sex, advanced age, BMI, active smoking, respiratory symptoms). To estimate the prevalence of "undiagnosed" subjects, defined as the presence of OVD without any known respiratory history, and to study their clinical characteristics. We plan to follow up with participants at 6 months through a telephone contact to assess the practical impact of this screening day and to determine the proportion of those who have received a consultation with a general practitioner, a pulmonologist, or the introduction of a treatment.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Séverine LABARRERE; Phone Number: +33559443828; Email: slabarrere@ch-cotebasque.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Population attending the "9 Mai Poumon 2026" prevention campaign

Description

• Inclusion criteria :
• Age ≥ 18 years
• Participating to the prevention campain "Mai Poumons 2026" on 09 Mai 2026
• Exclusion criteria :
• Contre-indication to perform a spirometry : hemoptysy, pneumothorax, myocardal infarction <1month, thoracic anevrism, recent ophtalmologic, abdominal or thoracic surgery
• Unable to perform a spirometry (understanding, coordination)
• Patient under legal protection
• Patient pregnant or breasting
• Not affiliating to public healthcare
• Patient deprived of liberty

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of newly diagnosed airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population	Percentage of AO and PRISm detected	On the day of inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of the clinical characteristics of patients with and without Airflow Obstruction / with and without PRISm	Percentage of presence of symptoms, specific treatment	At the day of inclusion
Description of the population participating to the prevention campaing	Percentage of presence of tabagism	At the day of inclusion
Evaluation of the number of patients diagnosed with airflow obstruction or Prism and who attend a consult with a medical doctor after the prevention campain	Percentage of patients with a medical follow-up at 6 months	At Month 6

Collaborators and Investigators

• Sponsor: Centre Hospitalier de la côte Basque

Study record dates

Study Major Dates

• Study Start (Estimated): May 9, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: May 4, 2026
• First Submitted That Met QC Criteria: May 4, 2026
• First Posted (Actual): May 8, 2026

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 11, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Respiratory System; Respiratory Function Tests; Spirometry
• Other Study ID Numbers: P-2026/07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No